Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Celcuity Inc is a diagnostics & research business based in the US. Celcuity shares (CELC) are listed on the NASDAQ and all prices are listed in US Dollars. Celcuity employs 30 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$27.09|
|52-week range||$5.00 - $32.00|
|50-day moving average||$24.69|
|200-day moving average||$20.74|
|Wall St. target price||$30.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.71|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||11.48%|
|3 months (2021-04-30)||-2.06%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-22.91%|
|Return on equity TTM||-38.03%|
|Market capitalisation||$305.4 million|
TTM: trailing 12 months
There are currently 332,052 Celcuity shares held short by investors – that's known as Celcuity's "short interest". This figure is 51% down from 678,132 last month.
There are a few different ways that this level of interest in shorting Celcuity shares can be evaluated.
Celcuity's "short interest ratio" (SIR) is the quantity of Celcuity shares currently shorted divided by the average quantity of Celcuity shares traded daily (recently around 215618.18181818). Celcuity's SIR currently stands at 1.54. In other words for every 100,000 Celcuity shares traded daily on the market, roughly 1540 shares are currently held short.
However Celcuity's short interest can also be evaluated against the total number of Celcuity shares, or, against the total number of tradable Celcuity shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celcuity's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Celcuity shares in existence, roughly 20 shares are currently held short) or 0.0398% of the tradable shares (for every 100,000 tradable Celcuity shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Celcuity.
Find out more about how you can short Celcuity stock.
We're not expecting Celcuity to pay a dividend over the next 12 months.
Over the last 12 months, Celcuity's shares have ranged in value from as little as $5 up to $32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celcuity's is 1.4983. This would suggest that Celcuity's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Celcuity Inc. , a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota. .
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.